{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:37:30Z","timestamp":1790753850287,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Futang Children Health Development Planning Foundation","award":["FTCSF-2018-03"],"award-info":[{"award-number":["FTCSF-2018-03"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960101"],"award-info":[{"award-number":["81960101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960443"],"award-info":[{"award-number":["81960443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangxi Province Health Committee Research Project","award":["20203689"],"award-info":[{"award-number":["20203689"]}]},{"name":"Jiangxi Province Health Committee Research Project","award":["202110098"],"award-info":[{"award-number":["202110098"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Surg Int"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00383-021-05043-5","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T11:02:27Z","timestamp":1642244547000},"page":"465-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib"],"prefix":"10.1007","volume":"38","author":[{"given":"Dou","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"issue":"12","key":"5043_CR1","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.jpedsurg.2015.08.035","volume":"50","author":"E Hiyama","year":"2015","unstructured":"Hiyama E et al (2015) Mortality and morbidity in primarily resected hepatoblastomas in Japan: experience of the JPLT (Japanese Study Group for Pediatric Liver Tumor) trials. J Pediatr Surg 50(12):2098\u20132101. https:\/\/doi.org\/10.1016\/j.jpedsurg.2015.08.035","journal-title":"J Pediatr Surg"},{"key":"5043_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2015.09.023","volume":"52","author":"P Czauderna","year":"2016","unstructured":"Czauderna P et al (2016) The children\u2019s hepatic tumors international collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 52:92\u2013101. https:\/\/doi.org\/10.1016\/j.ejca.2015.09.023","journal-title":"Eur J Cancer"},{"issue":"8","key":"5043_CR3","first-page":"1642","volume":"8","author":"LC DeBord","year":"2018","unstructured":"DeBord LC et al (2018) The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research. Am J Cancer Res 8(8):1642\u20131660","journal-title":"Am J Cancer Res"},{"issue":"3","key":"5043_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1293\/tox.2020-0007","volume":"33","author":"E Fujii","year":"2020","unstructured":"Fujii E, Kato A, Suzuki M (2020) Patient-derived xenograft (PDX) models: characteristics and points to consider for the process of establishment. J Toxicol Pathol 33(3):153\u2013160. https:\/\/doi.org\/10.1293\/tox.2020-0007","journal-title":"J Toxicol Pathol"},{"key":"5043_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01479","volume":"10","author":"Y Xin","year":"2020","unstructured":"Xin Y et al (2020) Establishment of a jaw fibrosarcoma patient-derived xenograft and evaluation of the tumor suppression efficacy of plumbagin against jaw fibrosarcoma. Front Oncol 10:1479. https:\/\/doi.org\/10.3389\/fonc.2020.01479","journal-title":"Front Oncol"},{"key":"5043_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4103\/0973-1482.139267","volume":"10","author":"S Rivankar","year":"2014","unstructured":"Rivankar S (2014) An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 10:853\u2013858. https:\/\/doi.org\/10.4103\/0973-1482.139267","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"5043_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/med.21280","volume":"34","author":"FS Carvalho","year":"2014","unstructured":"Carvalho FS et al (2014) Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34(1):106\u2013135. https:\/\/doi.org\/10.1002\/med.21280","journal-title":"Med Res Rev"},{"issue":"1","key":"5043_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1517\/14740330903446936","volume":"9","author":"T Limsuwan","year":"2010","unstructured":"Limsuwan T, Castells MC (2010) Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf 9(1):39\u201353. https:\/\/doi.org\/10.1517\/14740330903446936","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"5043_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","volume":"118","author":"B Han","year":"2018","unstructured":"Han B et al (2018) Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer 118(5):654\u2013661. https:\/\/doi.org\/10.1038\/bjc.2017.478","journal-title":"Br J Cancer"},{"issue":"1","key":"5043_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1530\/ERC-17-0558","volume":"26","author":"X Ruan","year":"2019","unstructured":"Ruan X et al (2019) Antitumor effects of anlotinib in thyroid cancer. Endocr Relat Cancer 26(1):153\u2013164. https:\/\/doi.org\/10.1530\/ERC-17-0558","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"5043_CR11","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1634\/theoncologist.2018-0839","volume":"24","author":"A-P Zhou","year":"2019","unstructured":"Zhou A-P et al (2019) Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. Oncologist 24(8):e702\u2013e708. https:\/\/doi.org\/10.1634\/theoncologist.2018-0839","journal-title":"Oncologist"},{"issue":"7","key":"5043_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","volume":"11","author":"F Song","year":"2020","unstructured":"Song F et al (2020) Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis 11(7):573. https:\/\/doi.org\/10.1038\/s41419-020-02749-7","journal-title":"Cell Death Dis"},{"issue":"1","key":"5043_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00280-020-04105-0","volume":"86","author":"S Noda","year":"2020","unstructured":"Noda S et al (2020) Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. Cancer Chemother Pharmacol 86(1):129\u2013139. https:\/\/doi.org\/10.1007\/s00280-020-04105-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"5043_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/oxfordjournals.annonc.a010500","volume":"7","author":"P Chollet","year":"1996","unstructured":"Chollet P et al (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7(10):1065\u20131070. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010500","journal-title":"Ann Oncol"},{"issue":"2","key":"5043_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40199-020-00374-5","volume":"28","author":"O Esim","year":"2020","unstructured":"Esim O et al (2020) Development, optimization and in vitro evaluation of oxaliplatin loaded nanoparticles in non-small cell lung cancer. DARU J Pharm Sci 28(2):673\u2013684. https:\/\/doi.org\/10.1007\/s40199-020-00374-5","journal-title":"DARU J Pharm Sci"},{"issue":"2","key":"5043_CR16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ehf2.12616","volume":"7","author":"R Tanaka","year":"2020","unstructured":"Tanaka R et al (2020) Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation. ESC Heart Fail 7(2):588\u2013603. https:\/\/doi.org\/10.1002\/ehf2.12616","journal-title":"ESC Heart Fail"},{"key":"5043_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pupt.2017.03.009","volume":"44","author":"G Kimura","year":"2017","unstructured":"Kimura G et al (2017) Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. Pulm Pharmacol Ther 44:46\u201349. https:\/\/doi.org\/10.1016\/j.pupt.2017.03.009","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"5043_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S0360-3016(01)02792-4","volume":"52","author":"A Cividalli","year":"2002","unstructured":"Cividalli A et al (2002) Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol*Biol*Phys 52(4):1092\u20131098. https:\/\/doi.org\/10.1016\/S0360-3016(01)02792-4","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"1","key":"5043_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s42003-021-02562-8","volume":"4","author":"A Bondoc","year":"2021","unstructured":"Bondoc A et al (2021) Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma. Commun Biol 4(1):1049\u20131049. https:\/\/doi.org\/10.1038\/s42003-021-02562-8","journal-title":"Commun Biol"},{"issue":"4","key":"5043_CR20","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/hep.31919","volume":"74","author":"ME Johnston Ii","year":"2021","unstructured":"Johnston Ii ME et al (2021) Olaparib inhibits tumor growth of hepatoblastoma in patient-derived xenograft models. Hepatology 74(4):2201\u20132215. https:\/\/doi.org\/10.1002\/hep.31919","journal-title":"Hepatology"},{"issue":"4","key":"5043_CR21","first-page":"1429","volume":"24","author":"R Xu","year":"2019","unstructured":"Xu R et al (2019) Clinical value of spectral CT imaging combined with AFP in identifying liver cancer and hepatic focal nodular hyperplasia. J B.U.ON: Off J Balkan Union Oncol 24(4):1429\u20131434","journal-title":"J B.U.ON: Off J Balkan Union Oncol"},{"issue":"3","key":"5043_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s13246-010-0026-4","volume":"33","author":"L Marcu","year":"2010","unstructured":"Marcu L, Bezak E (2010) Modelling of tumour repopulation after chemotherapy. Australas Phys Eng Sci Med 33(3):265\u2013270. https:\/\/doi.org\/10.1007\/s13246-010-0026-4","journal-title":"Australas Phys Eng Sci Med"},{"issue":"4","key":"5043_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1634\/theoncologist.12-4-465","volume":"12","author":"S Senan","year":"2007","unstructured":"Senan S, Smit EF (2007) Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12(4):465\u2013477. https:\/\/doi.org\/10.1634\/theoncologist.12-4-465","journal-title":"Oncologist"},{"issue":"1","key":"5043_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ncponc0403","volume":"3","author":"RK Jain","year":"2006","unstructured":"Jain RK et al (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3(1):24\u201340. https:\/\/doi.org\/10.1038\/ncponc0403","journal-title":"Nat Clin Pract Oncol"},{"key":"5043_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin B et al (2018) Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene 654:77\u201386. https:\/\/doi.org\/10.1016\/j.gene.2018.02.026","journal-title":"Gene"},{"issue":"1","key":"5043_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","volume":"21","author":"BI Rini","year":"2020","unstructured":"Rini BI et al (2020) Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol 21(1):95\u2013104. https:\/\/doi.org\/10.1016\/S1470-2045(19)30735-1","journal-title":"Lancet Oncol"},{"issue":"5","key":"5043_CR27","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-10-3126","volume":"71","author":"BL Falcon","year":"2011","unstructured":"Falcon BL et al (2011) Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1\/mTORC2 inhibitors. Can Res 71(5):1573. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3126","journal-title":"Can Res"},{"issue":"5","key":"5043_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s12094-017-1774-3","volume":"20","author":"C Yang","year":"2018","unstructured":"Yang C et al (2018) Ki67 targeted strategies for cancer therapy. Clin Transl Oncol 20(5):570\u2013575. https:\/\/doi.org\/10.1007\/s12094-017-1774-3","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"5043_CR29","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","volume":"11","author":"LT Li","year":"2015","unstructured":"Li LT et al (2015) Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep 11(3):1566\u20131572. https:\/\/doi.org\/10.3892\/mmr.2014.2914","journal-title":"Mol Med Rep"},{"key":"5043_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124473","author":"MJ Hsieh","year":"2020","unstructured":"Hsieh MJ et al (2020) Inactivation of APC induces CD34 upregulation to promote epithelial-mesenchymal transition and cancer stem cell traits in pancreatic cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21124473","journal-title":"Int J Mol Sci"}],"container-title":["Pediatric Surgery International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00383-021-05043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00383-021-05043-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00383-021-05043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T13:12:57Z","timestamp":1644498777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00383-021-05043-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5043"],"URL":"https:\/\/doi.org\/10.1007\/s00383-021-05043-5","relation":{},"ISSN":["0179-0358","1437-9813"],"issn-type":[{"value":"0179-0358","type":"print"},{"value":"1437-9813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"3 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there is no interest conflict.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments using immunodeficient mice were performed in accordance with guidelines approved by the Institutional Animal Care and Use Committee of Nanchang University. The study was approved by the Ethics Committee of Affiliated Children\u2019s Hospital of Nanchang University. Informed consent was obtained from the patient\u2019s guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}